Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
Status:
Completed
Trial end date:
2017-03-23
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the anti-tumor activity of oral Ixazomib as
measured by overall response rate (ORR) in adult participants with relapsed and/or refractory
follicular lymphoma (FL).